Immunotherapy before surgery for early rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage rectal cancer (T1 or T2) that has not spread to lymph nodes or other parts of the body.
- Your tumor must be MSS (microsatellite stable) or pMMR (proficient mismatch repair) based on a genetic test.
- You must be 18 years or older and in generally good health, able to perform daily activities without significant help.
- You have not had prior treatment for rectal cancer, including surgery, radiation, or chemotherapy.
- You have not received certain types of immunotherapy before, and you do not have active infections or autoimmune diseases that require treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Hear when a new Early Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.